Bianconi, D., Herac, M., Posch, F., Schmeidl, M., Unseld, M., Kieler, M., . . . Prager, G. (2020). Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: Results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol.

Bianconi, Daniela, et al. "Microvascular Density Assessed By CD31 Predicts Clinical Benefit Upon Bevacizumab Treatment in Metastatic Colorectal Cancer: Results of the PassionATE Study, a Translational Prospective Phase II Study of Capecitabine and Irinotecan Plus Bevacizumab Followed By Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients in MCRC." Ther Adv Med Oncol 2020.

Bianconi, Daniela, et al. "Microvascular Density Assessed By CD31 Predicts Clinical Benefit Upon Bevacizumab Treatment in Metastatic Colorectal Cancer: Results of the PassionATE Study, a Translational Prospective Phase II Study of Capecitabine and Irinotecan Plus Bevacizumab Followed By Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients in MCRC." Ther Adv Med Oncol 2020.